Fig. 6
From: DGCR2 targeting affibody molecules for delivery of drugs and imaging reagents to human beta cells

(A) Uptake of Indium-111 labeled Affibody molecules in kidney, urine and blood, based on ex vivo gamma counter measurements of excised tissues. (B) Biodistribution of [68Ga]ZDGCR2:AM106 by ex vivo organ distribution 60 min after injection. (C) Representative coronal PET/CT projections at 5 min, 30 min and 60 min after injection of [68Ga]ZDGCR2:AM106. (B) Biodistribution of [68Ga]ZDGCR2:AM106 in individual organs over time, from quantitative PET/CT scans.